HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sales & Earnings In Brief

This article was originally published in The Tan Sheet

Executive Summary

Chattem expects another "very good year": Chattem prepares to roll out at least six new products in 2009 and is "at a tipping point on moving to the next level," the Chattanooga, Tenn.-based company says. CEO and Chairman Zan Guerry explained during a Jan. 29 fourth-quarter earnings call that the firm has "the best new products line-up, the highest scoring advertising on the biggest promotions kicking off in February through June in history," making 2009 likely another strong year. In fiscal 2008, the firm's total revenues grew 7.4 percent to $454.9 million fueled primarily by the addition of brands acquired from Johnson & Johnson. The company's oral care category advanced 29 percent to $62.9 million and internal OTCs were up 7 percent to $48 million in the September-November period. Chattem's net income grew 11 percent to $66.3 million

You may also be interested in...

Arnold Leaves P&G After Reaching Top Of OTC, Personal Care Businesses

Susan Arnold has retired as the highest-ranking woman in Procter & Gamble's history, leaving a post that included supervising the pharmaceuticals, oral care, personal health and beauty divisions

Another PPI player

Takeda will launch its Rx proton pump inhibitor Kapidex (dexlansoprazole) despite a market filled with OTC alternatives, established brands and low-cost generics. The Japanese firm is banking on the drug's novel dual delayed-release formulation to differentiate it in a field that could soon include a generic version of its own Prevacid (lansoprazole), which Novartis licensed to develop. Takeda will need to market Kapidex in a manner similar to AztraZeneca's launch of Nexium (esomeprazole) when its Prilosec (omeprazole) went generic (1"The Tan Sheet" July 26, 2004, p. 8). The OTC PPI market also is more crowded after Procter & Gamble lost exclusivity for its Prilosec OTC in March 2008 and private label alternatives hit the market. P&G reported declines in Prilosec OTC sales since then, including a double-digit drop in its fiscal 2009 second quarter (2"The Tan Sheet" Feb. 2, 2009, p. 12). Novartis said it is "committed" to launching an OTC Prevacid, but the firm has not discussed the timing of the launch (3"The Tan Sheet" Jan. 19, 2009, p. 3)

Matrixx Initiatives Thrives In Cough/Cold, But Eyes Off-Season Relief

Matrixx Initiatives is looking at new products and possible acquisitions to help counter-balance the seasonality of its Zicam cough/cold, allergy and cold sore line, a goal that has so far eluded the firm

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts